- Home
- BCRX vs CVAC Comparison
BCRX vs CVAC Comparison
Compare BCRX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCRX
- CVAC
- Stock Information
- Founded
- BCRX 1986
- CVAC 2000
- Country
- BCRX United States
- CVAC Germany
- Employees
- BCRX N/A
- CVAC N/A
- Industry
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- BCRX Health Care
- CVAC Health Care
- Exchange
- BCRX Nasdaq
- CVAC Nasdaq
- Market Cap
- BCRX 1.4B
- CVAC 1.2B
- IPO Year
- BCRX 1994
- CVAC 2020
- Fundamental
- Price
- BCRX $7.12
- CVAC $5.48
- Analyst Decision
- BCRX Strong Buy
- CVAC Hold
- Analyst Count
- BCRX 11
- CVAC 3
- Target Price
- BCRX $19.00
- CVAC $6.83
- AVG Volume (30 Days)
- BCRX 4.8M
- CVAC 1.1M
- Earning Date
- BCRX 11-03-2025
- CVAC 11-24-2025
- Dividend Yield
- BCRX N/A
- CVAC N/A
- EPS Growth
- BCRX N/A
- CVAC 94.02
- EPS
- BCRX N/A
- CVAC 0.94
- Revenue
- BCRX $599,816,000.00
- CVAC $83,000,117.00
- Revenue This Year
- BCRX $41.57
- CVAC N/A
- Revenue Next Year
- BCRX $6.25
- CVAC $23.40
- P/E Ratio
- BCRX N/A
- CVAC $5.85
- Revenue Growth
- BCRX 45.38
- CVAC N/A
- 52 Week Low
- BCRX $6.00
- CVAC $2.48
- 52 Week High
- BCRX $11.31
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- BCRX 51.36
- CVAC 63.10
- Support Level
- BCRX $6.71
- CVAC $4.95
- Resistance Level
- BCRX $7.17
- CVAC $5.39
- Average True Range (ATR)
- BCRX 0.26
- CVAC 0.11
- MACD
- BCRX 0.01
- CVAC 0.01
- Stochastic Oscillator
- BCRX 67.42
- CVAC 97.22
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.